Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Probenecid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 known ✓ | Q4U2R8 | 1/20 | 0.97 |
| ▸ | SLC22A8 known ✓ | Q8TCC7 | 1/20 | 0.97 |
| ▸ | SLC22A11 known ✓ | Q9NSA0 | 1/20 | 0.97 |
| ▸ | CA9 | Q16790 | 14/20 | 0.97 |
| ▸ | CA12 | O43570 | 13/20 | 0.97 |
| ▸ | CA2 | P00918 | 5/20 | 0.97 |
| ▸ | RAB9A | P51151 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.97 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.97 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.97 |
| ▸ | CA1 | P00915 | 9/20 | 0.68 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probenecid SCHEMBL1034640 | 0.98 | CA9 (1.00) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL3663 | 0.98 | CA9 (1.00) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL22325443 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636803 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL28422402 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL23391020 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL23630240 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636778 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636804 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL28892826 | 0.97 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111386107-A | Use of probenecid in the treatment of an epileptic disease, disorder or condition | 巴黎科技与文学─拉丁区 | 2020-07-07 | — | — | CN | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| EP-3611249-A1 | ENHANCEMENT/OPTIMISATION OF HOPPING IN A WORT OR BEER PREPARATION PROCESS | Ziemann Holvrieka GmbH (DE) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| EP-3427729-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2019-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | SLC22A6 100/4885SLC22A8 62/4885SLC22A11 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.